IRCT2017013032236N2已完成2 期
Study of the efficacy and safety of memantine as an adjuvant to antipsychotics on improving positive and negative symptoms in patients with residual schizophrenia
Vice chancellor for research, Mazandaran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •1- Male or female are recruited from in-patient units in yahyaneghad hospital located in Babol in the north of Iran
- •2-18–65 years at the time of screening
- •3-With a diagnosis of schizophrenia(paranoid, disorganized, catatonic, or undifferentiated type)or schizoaffective disorder, based on the Structured Clinical Interview for DSM-V and they are suffering from the disease for more than 2 years with residual symptomatology despite antipsychotic treatment
- •4- All patients are on antipsychotics for at least 1 year and a stable dose for at least 2 month are included in the trial and the antipsychotics dose remain unchanged during the trial.
- •5-Mood stabilizers (lithium and divalproex) and antidepressants (only the selective serotonine reuptake inhibitors (SSRIs) venlafaxine, and mirtazapine) were permitted as part of antipsychotic pharmacotherapy. Dose of these drugs must be stable for at least 2 month remain unchanged during the trial.
- •Exclusions criteria:
- •1-Acute relapse (As acute relapse was defined an impending decompensation based on a PANSS score of =4 (moderately) on the subscore items of hostility and uncooperativeness and/or a =20% increase in the PANSS total score.
- •2-Psychiatric comorbidity(primary or secondary diagnosis of bipolar I disorder, either manic or mixed episode, as defined by DSM-V)
- •3-History of substance dependence (including alcohol, but excluding nicotine) as defined by DSM-V and relapse within the past 6 months, or substance abuse within the 3 months preceding the trial or positive urine test for illicit drugs
- •4-Electroconvulsive therapy during the 6 past months
- •5-Suicidality(active suicide or homicide intent, or a suicide or homicide attempt in the preceding 6 months)
- •6-Mental retardation
- •7-Pregnant or at risk of pregnancy
- •8-Cognitive disorders such as dementia, delirium, or amnesia, traumatic brain injury
- •9-Current significant unstable medical illness (such as unstable cardiac disease, hepatic or renal impairment, evidence or history of malignancy or any significant hematological, endocrine)/ HIV infection / abnormalities on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory values
- •10-Hypersensitivity to memantine
- •11-Previous treatment with memantine in the past year
- •12-History of neuroleptic malignant syndrome
- •13-Patients under treatment cholinesterase inhibitors, N-methyl D-aspartate (NMDA) receptor antagonists
- •14- Unwilling or unable, in the opinion of the Investigator, to comply with study instructions
排除标准
- 未提供
研究者
相似试验
招募中
3 期
Assessment the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathychemotherapy-induced peripheral neuropathy in patients with cancer.Idiopathic peripheral autonomic neuropathyG90.0IRCT20160310026998N12Tabriz University of Medical Sciences180
已完成
3 期
Evaluation of the effect of memantine for the prevention of headaches caused by head traumapost traumatic headache.post traumatic headacheG44.3IRCT20201005048944N1Esfahan University of Medical Sciences90
尚未招募
3 期
The effectiveness of the combination of Memantine and Betahistine on insomnia severity, quality of life and severity of symptoms in people with primary tinnitusTinnitusInsomniaIRCT20190427043389N4Zanjan University of Medical Sciences60
已完成
3 期
Comparing efficacy and side effects of Memantine and Risperidone in treating autistic patientsAutism.Pervasive developmental disordersIRCT201204037202N5Tehran University of Medical Sciences30
进行中（未招募）
不适用
Evaluation of the efficacy of memantine in the treatment of fibromyalgia: a double-blind randomized control clinical trial.FibromyalgiaEUCTR2011-006244-73-ESInstituto Aragonés de Ciencias de la Salud